[The preparation of patients with urinary stone disease to extracorporeal shock-wave lithotripsy]

Area of Science:

• Urology
• Nephrology
• Pharmacology

Background:

• Urinary stone disease presents complex challenges in urology.
• Citrate is a key natural inhibitor of urinary stone formation.
• Citrate-based therapies, including sodium and potassium citrate, are widely used.

Purpose of the Study:

• To evaluate the efficacy and safety of Uryklar, a dietary supplement, for treating ureteric stones.
• To assess the impact of Uryklar on stone size, density, and dissolution.

Main Methods:

• A study involving 57 patients with proximal ureteric stones was conducted.
• Patients received standard therapy; the intervention group additionally received Uryklar (405 mg TID for 1 month).
• Stone characteristics were assessed using multiplanar CT before and after treatment; symptoms and stone-free rates were evaluated via imaging and lab tests.

Main Results:

• Patients treated with Uryklar showed a significant reduction in stone size.
• Complete dissolution of stones was observed in some patients within the Uryklar group.
• The study assessed stone size, contour, density, and patient symptoms post-treatment.

Conclusions:

• Uryklar appears to be an effective and safe adjunct therapy for managing ureteric stones.
• The dietary supplement Uryklar may promote stone dissolution and improve stone-free rates.
• Further research could explore Uryklar's role in preventing stone recurrence.